Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during post-marketing studies. Therefore, we aimed to inve...
Zapisane w:
| Główni autorzy: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2022-08-01
|
| Seria: | Pharmaceuticals |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/1424-8247/15/9/1055 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|